- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05684640
A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety
A Single and Multiple Dose Study of Rodatristat Ethyl in Healthy Subjects to Evaluate the Effect of Food, and the Safety, Tolerability, and Pharmacokinetics of a Supratherapeutic Dose of Rodatristat Ethyl
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD Development
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males or females aged 18 to 55 years, inclusive.
- A male subject is eligible to participate if he does not have a female partner who is pregnant or who intends to become pregnant during the study. Male subjects must agree to use contraception starting at Screening, during the treatment period, and for at least 100 days after the last dose of study drug, and refrain from donating sperm during this period.
- Female subjects of childbearing potential must agree to use contraception starting at Screening, during the treatment period, and for at least 4 weeks after the last dose of study drug.
- Body mass index (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2.
- Willing and able to give written informed consent and to comply with the requirements of the study for its duration.
Exclusion Criteria:
As determined by the Investigator, any known pre existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to a history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, or cardiovascular disease, including
- History of Gilbert's Syndrome
- History of depression
- History of any allergy that, in the opinion of the Investigator, contraindicates participation in the trial
- Positive pregnancy test at Screening or Check-in.
- Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days or more than 499 mL within 56 days prior to starting study drug.
- Participation in an investigational drug, vaccine, or device study within 30 days before study drug administration or 90 days for a biologic study.
- Clinically significant ECG abnormalities.
- Abnormal blood pressure, either low (defined as < 90 mmHg systolic and/or < 50 mmHg diastolic) or high (defined as > 140 mmHg systolic and/or > 90 mmHg diastolic) at Screening or prior to starting study drug.
Clinically significant abnormalities in laboratory test results, as determined by the Investigator, (including hepatic and renal panels, complete blood count, coagulation, chemistry panel, and urinalysis) at Screening or Check-in.
- Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- Estimated glomerular filtration rate < 90 mL/min/1.73 m2 at Screening, calculated using the Modification of Diet in Renal Disease (MDRD) formula.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) values greater than upper limit of normal (ULN).
- Positive urine test for drugs of abuse at Screening or Check-in.
- Positive alcohol test (breath, saliva, or urine) at Screening or Check-in.
- Positive pregnancy test at Screening or Check-in.
- Use of prescription or nonprescription drugs, (with exception of contraceptive and acetaminophen allowance), including high dose vitamins, dietary supplements (including St. John's Wort) within 14 days or 5 half lives of the prescription or nonprescription drug (whichever was longer) prior to the first dose of study drug, through to the final follow-up visit.
- Consumption of grapefruit or Seville oranges or their juices within the 7 days prior to dosing until collection of the final PK sample.
- Use of medications associated with QT prolongation within 30 days prior to dosing and during the study.
- Subjects unable to abstain from alcohol for 72 hours prior to the start of dosing through collection of the final PK sample.
- Subjects with a clinical history of or current alcohol abuse defined as an average weekly intake of more than 21 units for males or 15 units for females (1 unit = 340 mL beer, 115 mL wine, or 43 mL spirits).
- Subjects with a clinical history of or current illicit drug use which, in the opinion of the Investigator, would interfere with the subject's ability to complete the study.
- Subjects unable to abstain from caffeine, xanthine, or strenuous exercise for 72 hours prior to dosing.
- Subjects who have smoked or used tobacco- or nicotine containing products within 3 months prior to the Screening visit and who are unwilling to refrain from smoking, tobacco use, or use of nicotine products for the entire duration of the study.
- Employed as site personnel directly involved with this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rodatristat ethyl
Part One: is 600 QD
|
Tablets, Oral, 600mg, QD
|
Placebo Comparator: Placebo
Part Two: Placebo match for Rodatristat ethyl
|
Tablets, Oral, 600mg, QD
Tablets, Oral, 0mg, BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 will evaluate the effect of a high-fat meal on the PK of rodatristat ethyl, rodatristat, and its metabolite(s) following single-dose administration of a rodatristat ethyl 600 mg dose
Time Frame: 6 Days
|
Measure Rodatristat, rodatristat ethyl, and its metabolite(s): Maximum plasma concentration Cmax, area under the plasma concentration-time curve from time zero (predose) to the last detectable time point.
|
6 Days
|
Part 2 will assess the PK of rodatristat ethyl, rodatristat, and metabolite(s) following multiple repeat doses of rodatristat ethyl at a supratherapeutic level
Time Frame: 11 Days
|
Measure PK parameters, area under the concentration time curve over the dosing interval.
|
11 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 will also evaluate the effect of a high-fat meal on other PK parameters of rodatristat ethyl, rodatristat, and its metabolites
Time Frame: 6 Day
|
Measure PK parameters: time to maximum concentration (tmax).
|
6 Day
|
Part 1 will also evaluate the effect of a high-fat meal on other PK parameters of rodatristat ethyl, rodatristat, and its metabolites
Time Frame: 6 Day
|
Measure elimination of half life (t 1/2)
|
6 Day
|
Part 2 will also assess the effect of a supratherapeutic dose of rodatristat ethyl on plasma 5 hydroxyindoleacetic acid (5 HIAA) concentrations
Time Frame: 11 Days
|
Measure changes from baseline in plasma 5-HIAA concentrations from Baseline
|
11 Days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas Hunt, MD, PPD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RVT-1201-1006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Rodatristat Ethyl
-
Altavant Sciences GmbHCompletedPulmonary Arterial HypertensionUnited States, Spain, United Kingdom, Czechia, Serbia, Canada, Poland, Italy, Bosnia and Herzegovina, Austria, Germany, Belgium, Bulgaria, France, Latvia, Moldova, Republic of, Ukraine
-
Altavant Sciences GmbHParexel; Altavant Sciences, Inc.Completed
-
Altavant Sciences GmbHCovance; Altavant Sciences, Inc.Completed
-
Altavant Sciences GmbHPPD; Altavant Sciences, Inc.TerminatedPulmonary Arterial HypertensionUnited States, Canada
-
Altavant Sciences GmbHAltasciences Clinical Kansas, Inc.Completed
-
Unilever R&DLeiden University Medical CenterCompleted
-
New York State Psychiatric InstituteWithdrawnBipolar DisorderUnited States
-
TerSera Therapeutics LLCCompletedCarcinoid SyndromeUnited States
-
University of Missouri-ColumbiaNot yet recruiting
-
National Center for Complementary and Integrative...CompletedDepressive Disorder | DepressionUnited States